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Activation of the DNA replication checkpoint by the
ATR kinase requires protein interactions mediated
by the ATR-activating protein, TopBP1. Accumula-
tion of TopBP1 at stalled replication forks requires
the interaction of TopBP1 BRCT5 with the phosphor-
ylated SDT repeats of the adaptor protein MDC1.
Here, we present the X-ray crystal structures of the
tandem BRCT4/5 domains of TopBP1 free and in
complex with a MDC1 consensus pSDpT phospho-
peptide. TopBP1 BRCT4/5 adopts a variant BRCT-
BRCT packing interface and recognizes its target
peptide in a manner distinct from that observed in
previous tandem BRCT- peptide structures. The
phosphate-binding pocket and positively charged
residues in a variant loop in BRCT5 present an
extended binding surface for the negatively charged
MDC1 phosphopeptide. Mutations in this surface
reduce binding affinity and recruitment of TopBP1
to gH2AX foci in cells. These studies reveal a different
mode of phosphopeptide binding by BRCT domains
in the DNA damage response.
INTRODUCTION
The DNA replication checkpoint is crucial for the prevention of
genomic instability during DNA replication in cells. Activation of
the DNA replication checkpoint requires the orchestrated as-
sembly of proteins at the stalled replication fork. Topoisomerase
IIb binding protein 1 (TopBP1) is key to the success of DNA repli-
cation checkpoint activation by operating at multiple and distinct
steps that contribute to the robust activation of the critical Ser/
Thr kinase, ataxia telangiectasia and Rad3 related (ATR). The
abundance of conserved phosphopeptide binding BRCA1
C-terminal (BRCT) domains in TopBP1 provides extraordinary
specificity to target different replication fork proteins. The
TopBP1 N-terminal BRCT0/1/2 domains recognize the Rad9
C-terminal tail of the Rad9-Rad1-Hus1 (9-1-1) complex to acti-
vate ATR via the ATR activation domain (AAD) of TopBP1 (Dela-
croix et al., 2007; Lee et al., 2007). ATR kinase activity is further
potentiated by a secondary interaction between the TopBP11450 Structure 21, 1450–1459, August 6, 2013 ª2013 Elsevier Ltd AlC-terminal BRCT7/8 domains and autophosphorylated ATR
(Liu et al., 2011). In an earlier step in checkpoint activation, the
TopBP1 BRCT7/8 domains bind BRCA1-associated C-terminal
helicase/Fanconi anemia group J protein (BACH1/FANCJ) to
regulate the helicase activity of BACH1 and increase single-
stranded DNA and subsequent replication protein A loading
(Gong et al., 2010). Despite these findings, it remained elusive
how TopBP1 accumulates at stalled replication forks because
TopBP1 localization is independent of BACH1 and Rad9 inter-
actions (Gong et al., 2010; Yan and Michael, 2009).
We have shown that the fifth BRCT domain of TopBP1 is
responsible for TopBP1 localization to stalled replication forks
(Wang et al., 2011; Yamane et al., 2002). TopBP1 BRCT5 directly
interacts with the phosphorylated Ser-Asp-Thr (SDT) repeats in
mediator of DNA damage checkpoint protein 1 (MDC1), and
this binding is required for sustaining and amplifying ATR activity
for checkpoint activation (Wang et al., 2011). MDC1 is a critical
DNA damage response (DDR) adaptor in DNA double-strand
break (DSB) repair. The rapid phosphorylation of histone H2AX
at Ser139 (g-H2AX) by the Ser/Thr kinase ATM is recognized
by the tandem BRCT domains of MDC1, which further functions
as a platform to bind various DDR factors such as RNF8 and the
MRE11-RAD50-NBS1 (MRN) complex (Huen and Chen, 2010).
A region in MDC1 spanning amino acids 210–460 contains six
highly conserved SDT motifs that are constitutively phosphory-
lated by casein kinase 2 (CK2). These diphosphorylated motifs
are recognized by the FHA-BRCT-BRCT domain repeat in
NBS1 (Chapman and Jackson, 2008; Melander et al., 2008;
Spycher et al., 2008; Wu et al., 2008; Xu et al., 2008) and by
the FHA domain of aprataxin (Becherel et al., 2010).
BRCT domains are versatilemodules that form various domain
assemblies and are implicated in numerous functions, including
protein-protein, phosphopeptide, DNA, and poly(ADP-ribose)
binding (Leung and Glover, 2011). The conserved mode of
phosphopeptide recognition by tandem BRCT domains is well
established through structural studies in DDR proteins such as
BRCA1, MDC1, TopBP1, MCPH1, S. pombe Crb2, and
S. pombe Brc1 (Clapperton et al., 2004; Kilkenny et al., 2008;
Leung et al., 2011; Shiozaki et al., 2004; Singh et al., 2012; Stucki
et al., 2005; Williams et al., 2004, 2010). The tandem BRCT
presents an extended phosphopeptide binding surface, with a
pSer/pThr binding pocket located at the N-terminal BRCT
domain and a secondary pocket at the BRCT-BRCT interface
with specificity for +3 or +3/+4 residues. Unlike conventional
tandem BRCT domains that require both BRCT domains tol rights reserved
Table 1. Data Collection, Phasing, and Refinement Statistics
Data Collection TopBP1 BRCT4/5
TopBP1 BRCT4/5-
Peptide Complex
Space group P2221 P1
Cell dimensions
a, b, c (A˚) 35.90, 48.80, 126.09 58.81, 59.10, 78.31
a, b, g () 90.00, 90.00, 90.00 102.05, 98.04, 114.34
Resolution (A˚) 63.04–1.90 34.57–2.60
Rsym
a 0.077 (0.497) 0.059 (0.402)
I/sI 18.0 (2.5) 11.9 (2.2)
Completeness (%) 99.8 (99.2) 95.2 (95.2)
Redundancy 3.8 (3.7) 2.1 (2.1)
Refinement
Resolution (A˚) 38.60–1.90 34.57–2.60
No. reflections 18,137 (927) 26,637 (1,330)
Rwork/Rfree
b 0.175/0.224 0.190/0.234
No. of atoms
Protein 1,540 5,716
Peptide – 159
Ligand 33 –
Water 238 257
Average B factor (A˚2)
Protein 11.0 44.3
Peptide – 58.6
Ligand 31.9 –
Water 23.7 33.6
Rmsd
Bond lengths (A˚) 0.011 0.009
Bond angles () 1.347 1.132
aRsym = SjIhIij/SjIj.
bR =SjjFojjFcjj/SjFoj,Rfreewas calculated from 5%of the data excluded
from refinement.
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Structural Insights into MDC1-TopBP1 Interactionform a viable phosphopeptide binding surface, only the
C-terminal BRCT5 of the tandem BRCT4/5 pair is needed for
MDC1 interaction and indeed BRCT4 lacks key amino acids
required for phosphopeptide recognition (Rappas et al., 2011).
In light of this knowledge, we sought to delineate the molecular
basis of TopBP1-MDC1 interaction by characterizing, both
structurally and functionally, the interaction between the tandem
TopBP1 BRCT4/5 domains and a MDC1 diphosphopeptide
containing a consensus sequence of the SDT repeats. We
show that TopBP1 BRCT4/5 adopts an unconventional tandem
BRCT repeat structure with a phosphate-binding pocket in the
C-terminal BRCT5 domain. The combination of the phosphate-
binding pocket and a structured loop in BRCT5 creates an
extended positively charged surface that mediates MDC1 SDT
diphosphopeptide binding and TopBP1 accumulation to stalled
replication forks.
RESULTS
Crystal Structure of TopBP1 BRCT4/5
The crystal structure of TopBP1 BRCT4/5 was solved to 1.9 A˚
resolution (Table 1). The tandem BRCT pair adopts a distinctStructure 21, 1450domain packing, where the juxtaposition of the two BRCT do-
mains is head-to-head (where head is defined as the a1-a3
face and tail as the a2 face) rather than the head-to-tail arrange-
ment characteristic of canonical BRCT repeats (Figure S1A avail-
able online). This is likely driven by a combination of the variant
BRCT fold in the N-terminal BRCT4 and a significantly shorter
linker region between BRCT4 and BRCT5 (Figure 1A; Fig-
ure S1B). TopBP1 BRCT4 lacks an a2 helix, which in canonical
BRCT repeats houses conserved residues that participate in
phosphate binding and the hydrophobic BRCT-BRCT interface.
Instead, the BRCT4 a2 is replaced by a short loop that is solvent
exposed rather than being involved at the BRCT-BRCT interface.
A short linker helix (aL) composed of three residues (Pro632,
Leu633, and Phe634) is also part of a significantly shorter inter-
BRCT linker in TopBP1 BRCT4/5 (Figure 1A). The inter-BRCT
linker packs tightly between the adjacent BRCT domains to sta-
bilize the BRCT-BRCT interface.
Because of the unusual head-to-head domain arrangement,
the composition of the N-terminal domain face that contacts
the C-terminal domain is significantly different from the one
used in conventional BRCT repeats. The N-terminal domain
face consists of residues from a3 (Val617 and Thr618), the b3-
b4 loop (Leu598 and Leu599), and linker region (Pro632,
Leu633, Val637, Pro638, and Val639; Figure 1B, left). Contribu-
tions from these different regions substitute for the a2 helix typi-
cally used in the canonical interface. Conversely, the C-terminal
domain face that contacts the N-terminal domain involves the a1
0
and a3
0 helices, which are the same secondary structure ele-
ments used in canonical BRCT repeats. Residues that form
this hydrophobic face include Ala659, Ser663, Leu664,
Phe666, Leu667, and Leu670 of a1
0 and Ile718, Leu722,
Ala725, and Arg726 of a3
0 (Figure 1B, right). Together, the a3,
b3-b4 loop, linker region, a1
0 and a30 helices form an extensive
hydrophobic interface that enables a head-to-head domain
packing in TopBP1 BRCT4/5.
To date, the phosphate-binding pockets identified in canoni-
cal BRCT repeats are found in the N-terminal BRCT. This en-
ables the characteristic specificity for the +3 residue in a targeted
phosphopeptide through a secondary pocket formed at the
BRCT-BRCT interface. Besides being positioned on the oppo-
site side of the canonical phosphopeptide binding surface, the
putative phosphate-binding pocket in BRCT4 is highly acidic,
and conserved phosphate-binding residues are instead
substituted with Leu561, Glu568, and Glu604 (Figure 1C, left).
Strikingly, an intact phosphate-binding pocket containing the
conserved Ser654, Lys661, and Lys704 residues is instead
found in the C-terminal BRCT5 (Figure 1C, right). Although the
presence of a C-terminal phosphate-binding pocket is perplex-
ing in comparison to other BRCT repeats, the possibility for
BRCT5 to recognize a phosphate supports previous findings
that BRCT5 interacts with phospho-MDC1 to control the DNA
replication checkpoint (Wang et al., 2011).
To probe for potential protein binding surfaces on TopBP1
BRCT4/5, we first examined the electrostatic potential surface
of TopBP1BRCT4/5. Although the BRCT repeat structure carries
an overall negative charge, a highly positively charged surface is
located in BRCT5 (Figure 1D, left). This region is rich in basic res-
idues that extend from the putative phosphate-binding pocket
(Lys661 and Lys704) to the extended b2
0-b30 loop (Arg681,–1459, August 6, 2013 ª2013 Elsevier Ltd All rights reserved 1451
Figure 1. Crystal Structure of TopBP1
BRCT4/5
(A) Cartoon representation of TopBP1 BRCT4/5.
BRCT4 (light green), BRCT5 (dark green), and the
linker region (red) are colored accordingly. Sec-
ondary structure elements are labeled.
(B) BRCT-BRCT interface of TopBP1 BRCT4/5.
Residues involved in the hydrophobic packing for
the N-terminal face (left) and C-terminal face (right)
are shown as sticks and labeled. The opposing
interface is shown as transparent.
(C) Comparison of conserved phosphate-binding
residues in BRCT4 (left) and BRCT5 (right).
(D) Electrostatic surface representation of TopBP1
BRCT4/5 oriented with BRCT4 on the left and
BRCT5 on the right (left). The positively charged
surface of BRCT5 is boxed. Residues that make up
the BRCT5 phosphate-binding pocket and posi-
tively charged surface are shown as sticks and
labeled (right).
See also Figure S1.
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Structural Insights into MDC1-TopBP1 InteractionLys682, Lys686, and Lys687) and C terminus of a2
0 (Lys710; Fig-
ure 1D, right). Alignments of various tandemBRCT domains indi-
cate that the b2
0-b30 loop is the most variable region in the BRCT
family (Glover et al., 2004). In TopBP1 BRCT5, the b2
0-b30 loop
adopts an unusually extended, structured protrusion. A series
of main chain hydrogen bonds mediated by Asn684, Ala685,
Lys687, Gly688, Met689, and Ala691 ensure rigidity of the loop
(Figure S1C). The side chains of Asn684 and Ser683 also partic-
ipate in hydrogen bonds with the loop main chain. This provides
a structural platform for the four basic loop residues (Arg681,
Lys682, Lys686, and Lys687) to create a positively charged
concave pocket. Furthermore, the loop residues, especially
Asn684 and the group of basic residues, are conserved in other
species (Figure S1D).
TopBP1 BRCT4/5 Binds Phosphorylated MDC1 SDT
Repeats
We have previously shown that TopBP1 BRCT5 interacts with a
MDC1 diphosphopeptide encoding a consensus sequence of
the six SDT repeats (Figure S2A; Wang et al., 2011). To further
characterize binding specificities of this interaction in vitro, we
used a fluorescence polarization (FP) assay. Using this assay,
we tested for the ability of GST fusion proteins of TopBP1
BRCT5 and BRCT4/5 to bind a FITC-labeled MDC1 consensus1452 Structure 21, 1450–1459, August 6, 2013 ª2013 Elsevier Ltd All rights reservedSDT diphosphopeptide (GFIDpSDpTD
VEEE). GST-BRCT4/5 and GST-BRCT5
bound the phosphopeptide with essen-
tially identical affinities (Kd = 28 ± 4 mM
for GST-BRCT5, Kd = 27 ± 4 mM for
GST-BRCT4/5), indicating that BRCT4 is
not important for the MDC1 interaction
(Figure 2A, upper; Table 2).We next tested
the importance of Ser/Thr phosphoryla-
tion for TopBP1 binding. A nonphosphory-
lated version of the SDT peptide bound
TopBP1 BRCT5, albeit with a significant
(11-fold) reduction in binding affinity
(Figure 2A, lower; Table 2). We alsocompared the affinity of TopBP1 BRCT5 affinity for doubly phos-
phorylatedMDC1 peptides withMDC1 peptides bearing a single
phosphate at either the Ser or Thr positions. The results indicate
that either singly phosphorylated peptide is bound with a
somewhat reduced (3.5-fold) affinity compared to the doubly
phosphorylated version (Figure 2A, lower; Table 2). This result
indicates that both residues play a role in TopBP1 binding. The
importance of phosphorylation for this interaction appears to
be significantly less than that for other BRCT-phosphopeptide
interactions. For example, TopBP1 BRCT7/8 binds its phosphor-
ylated target peptide from BACH1 100-fold more tightly than
the dephosphorylated peptide (Gong et al., 2010). This suggests
that the mechanism of peptide recognition used by BRCT4/5
may be significantly different from that of other tandem BRCT
repeats.
Crystal Structure of TopBP1 BRCT4/5 Bound to
Phosphorylated MDC1
To further investigate the TopBP1-MDC1 interaction, we cocrys-
tallized and solved the structure of TopBP1 BRCT4/5 in complex
with a MDC1 diphosphopeptide to 2.6 A˚ resolution. A single
MDC1 diphosphopeptide is bound in an extended conformation
by two BRCT4/5 protomers on opposite sides (represented as
protomers A and B, Figure 2B). The peptide-bound dimer is
Figure 2. MDC1 SDT Diphosphopeptide Inter-
actions with TopBP1 BRCT4/5
(A) FP binding results for the MDC1 FITC-labeled di-
phosphopeptide and various TopBP1 proteins. Trip-
licate data points are represented in graphs as
mean ± SEM. (Top) FITC-peptide binding results for
GST, GST-fusion proteins of BRCT4/5 and BRCT5,
as well as untagged BRCT4/5 and MBP-BRCT4/5.
(Bottom) FP assay of nonphosphorylated, pSer, pThr
or diphosphorylated MDC1 FITC-labeled peptide
with GST-TopBP1 BRCT5.
(B) Crystal structure of MDC1 diphosphopeptide in
complex with TopBP1 BRCT4/5. The phosphorylated
residues of the peptide (yellow) are labeled. BRCT4/5
protomer A (blue) and B (teal) are designated.
(C) Diphosphopeptide interactions with BRCT5 (rep-
resented in surface representation) of protomer A
(left) and protomer B (right). The 2jFojjFcj electron
density map for the diphosphopeptide is shown
in magenta and peptide-interacting residues are
labeled.
See also Figure S2.
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Structural Insights into MDC1-TopBP1 Interactionfurther related by 2-fold noncrystallographic symmetry with
another peptide-bound dimer in the asymmetric unit (Fig-
ure S2B). Comparisons of the apo and bound structures indicate
that BRCT4/5 is structurally rigid and does not change signifi-
cantly upon peptide binding (root-mean-square deviation
[rmsd] for Ca = 0.39 and 0.46 with protomers A and B, respec-
tively). The two protomers are oriented in an orthogonal manner
in the dimer and interact indirectly through the MDC1 diphos-
phopeptide, except for a single hydrogen bond between the
Tyr622 side chain of protomer A and the Gly702 main chain of
protomer B. Consistent with previous data for BRCT5-mediated
MDC1 binding, the MDC1 diphosphopeptide exclusively con-
tacts the two BRCT5 domains from each protomer. Although
the MDC1 diphosphopeptide interacts with two BRCT5 do-
mains, their binding interfaces are not symmetrical and differ in
size and composition. The majority of interactions with protomer
A are contributed by the peptide pThr residue and bury a total
solvent accessible surface area of 434 A˚2 (Figure 2C). This rela-
tively small contact interface suggests that peptide interactions
with protomer A are unlikely to be stable on its own and indeed
some of the crystal contacts actually bury a larger surface area
than the protomer A-peptide interface. In contrast, the interface
between the diphosphopeptide and protomer B is more exten-
sive, spanning residues3 to +4 relative to the pThr and burying
919 A˚2 of solvent-accessible surface area (Figure 2C).
To test the possibility that two protomers of TopBP1 could
bind to a MDC1 diphosphopeptide in solution, we assessed
the impact of enforced dimerization on the peptide binding affin-Structure 21, 1450–1459, August 6, 201ity of TopBP1. We compared the MDC1
diphosphopeptide binding affinities of
GST-BRCT4/5 or GST-BRCT5, which both
exist as dimers in solution, with monomeric
forms of TopBP1 BRCT4/5 (Figure 2A,
upper). The GST fusion-stabilized dimers
bind MDC1 3-fold tighter than either the
free BRCT4/5 or MBP-BRCT4/5, which are
both monomeric as determined with gelfiltration chromatography (Kd = 82 ± 16 mM for MBP-BRCT4/5;
Kd = 94 ± 15 mM for untagged BRCT4/5). The enhanced affinity
of the dimeric forms of TopBP1 over the monomeric forms
is consistent with an avidity effect that would be expected
in a structure where two protomers bind the MDC1
diphosphopeptide.
TopBP1 BRCT4/5-MDC1 SDT Repeat Binding
Interactions
Unlike the highly specific phosphate-binding properties of ca-
nonical tandem BRCT domain pockets, peptide recognition by
the BRCT5 phosphate-binding pocket relies more on general
charge-charge interactions and water-mediated contacts. Inter-
actions with BRCT5 of protomer A involve the MDC1 pThr and
1 Asp. The pThr is coordinated in the phosphate-binding
pocket, but only participates in a single direct interaction with
the conserved Lys704 side chain, although it makes water-
mediated interactions with the main chain of Cys656 and
Lys704 and side chain of Ser703 of protomer B (Figure 3A). Be-
sides the pThr, the 1 Asp side chain also hydrogen bonds to
the Ser703 main chain of protomer A. Unexpectedly, the 3
Asp, rather than the 2 pSer, points into the phosphate-binding
pocket of protomer B (Figure 3B). The 2 pSer instead lies
across the phosphate-binding pocket of protomer B. The 3
Asp side chain hydrogen bonds with the Gln655 main chain
and Ser654 side chain, as well as the Lys704 side chain through
a water molecule. Other contacts include a main chain–main
chain hydrogen bond between the +1 Asp and Phe679 and3 ª2013 Elsevier Ltd All rights reserved 1453
Table 2. Summary of Fluorescence Polarization Binding
Experiments
Protein Peptide Kd (mM)
GST-BRCT5 FITC-GFIDSDTDVEEE-NH2 310 ± 70
FITC-GFIDpSDTDVEEE-NH2 105 ± 9
FITC-GFIDSDpTDVEEE-NH2 98 ± 9
FITC-GFIDpSDpTDVEEE-NH2 28 ± 4
FITC-GFIDpSDpTDDEEE-NH2 24 ± 3
GST-BRCT4/5 FITC-GFIDpSDpTDVEEE-NH2 27 ± 4
MBP-BRCT4/5 FITC-GFIDpSDpTDVEEE-NH2 82 ± 16
BRCT4/5 FITC-GFIDpSDpTDVEEE-NH2 94 ± 15
GST FITC-GFIDpSDpTDVEEE-NH2 ND
GST-BRCT5 Mutants
S654A FITC-GFIDpSDpTDVEEE-NH2 32 ± 3
R681E/K682E FITC-GFIDpSDpTDVEEE-NH2 280 ± 60
K704A FITC-GFIDpSDpTDVEEE-NH2 210 ± 50
ND, not determined.
Structure
Structural Insights into MDC1-TopBP1 Interactionwater-bridged interactions involving the Tyr678 side chain and
the 1 and +1 Asp side chains.
Perhaps the most extensive interaction surface involves the
recognition of the C-terminal residues of the conserved MDC1
SDT motif. As part of the larger binding interface established
by protomer B, the +2 to +4 residues are recognized by the
BRCT5 basic surface that extends from the phosphate-binding
pocket to the b2
0-b30 loop. The +2 Val sits in a small hydrophobic
pocket situated between the basic phosphate-binding pocket
and b2
0-b30 loop (Figure 3C). Residues that contribute to this
pocket include Ala707 and Trp711 from a2
0 and Phe679 from
the b2
0-b30 loop. The conserved +3 and +4 Glu residues are
cradled in the positively charged b2
0-b30 loop. The +3 main chain
hydrogen bonds with the main chain of Phe679 and Arg681
(Figure 3B), while the +3 and +4 acidic side chains make electro-
static interactions with Lys687 and Lys682, respectively (Fig-
ure 3C). Overall, the makeup of the BRCT5 binding surface
matches the conservation of a small hydrophobic residue at +2
and acidic residues at +3 and +4 positions of the MDC1 SDT re-
peats (Figure S2A). The interactions between both protomers
and the MDC1 diphosphopeptide are summarized in Figure 3D.
To test the importance of the conserved hydrophobic Val res-
idue at the peptide +2 position, we compared the binding affinity
of the wild-type MDC1 phosphopeptide with that of a peptide in
which the +2 Val is substituted with an Asp. While a Val is the
most common residue at this position, one of the MDC1 SDT re-
peats harbors an Asp at this position. We reasoned that if inter-
actions between the diphosphopeptide and BRCT5 are purely
electrostatic, then an increase in the overall negative charge of
the peptide should enhance binding affinity. If instead the hydro-
phobic interactions involving the +2 residue are critical, then the
substitution should reduce binding affinity. We observe, how-
ever, that the substitution results in no significant change in bind-
ing affinity (Figure S3A; Table 2). Thismay indicate that the loss in
hydrophobic interactions in the mutant is balanced by long-
range electrostatic interactions between the substituted Asp
and the surrounding positively charged surface of BRCT5 and in-
dicates that each of the SDT repeats are equally capable of bind-1454 Structure 21, 1450–1459, August 6, 2013 ª2013 Elsevier Ltd Aling TopBP1. The results suggest that the pocket may function
to restrict the +2 residue to either a small hydrophobic residue
or an Asp.
Mutational Analysis of BRCT5 Binding Interface
Because TopBP1 BRCT5 facilitates TopBP1 localization at
stalled replication forks, we first generated several mutants
within the BRCT5 domain and tested their abilities to form hy-
droxyurea (HU)-induced foci in cells. Mutations in the putative
phosphate-binding pocket (K704A) or in the b2
0-b30 loop
(R681E/K682E) abolished foci formation, supporting the require-
ment for the positively charged BRCT5 surface (Figure 4A). In
contrast, the S654Amutation did not disrupt TopBP1 foci forma-
tion but did appear to give less intense foci compared to back-
ground nuclear fluorescence in these cells. This is in agreement
with the observation that the conserved Ser654 in the BRCT5
phosphate-binding pocket does not appear to have a major
role in binding the MDC1 diphosphopeptide in the crystal struc-
ture. In contrast, the analogous Ser/Thr is required for phospho-
peptide binding in several conventional tandem BRCT domains
such as BRCA1, MDC1, and TopBP1 BRCT7/8, highlighting
the distinct mechanism of phosphopeptide recognition used
by TopBP1 BRCT4/5 (Leung and Glover, 2011). We next per-
formed FP studies on various BRCT5 mutants to test whether
the conserved positively charged surface is responsible for inter-
actions with MDC1 in vitro. Consistent with TopBP1 localization,
mutations in either the putative phosphate-binding pocket
(K704A) or b2
0-b30 loop (R681E/K682E) in GST-fusion proteins
of BRCT5 significantly reduced binding to the MDC1 diphospho-
peptide compared with wild-type (Kd 210 ± 50 mM for K704A,
Kd 280 ± 60 mM for R681E/K682E; Figure 4B). In contrast, the
S654A mutant bound the MDC1 diphosphopeptide with an
affinity very similar to wild-type (Kd = 32 ± 3 mM). Overall, the
specificity for theMDC1SDTmotif correlates with ourmutational
analysis and provides a rationale for the unusually structured and
positively charged b2
0-b30 loop exclusive to TopBP1 BRCT5.
DISCUSSION
The recognition of MDC1 by TopBP1 is critical for DNA replica-
tion checkpoint control in response to replication stress. TopBP1
BRCT5 directly binds to the conserved SDT repeats of MDC1,
and this interaction is necessary for sustaining and amplifying
ATR activation. In the context of phosphopeptide recognition
by BRCT domains, the interaction between TopBP1 BRCT5
and the MDC1 SDT motifs was intriguing for several reasons.
As part of a tandem BRCT pair, the functional requirement for
only the C-terminal BRCT5 domain suggested that TopBP1
BRCT4/5 does not follow the canonical BRCT repeat mode of
recognition (Wang et al., 2011; Yamane et al., 2002). The
MDC1 SDT repeats are established diphosphopeptide motifs
that are also targets for the FHA domains of NBS1 and Aprataxin
in DNA repair (Becherel et al., 2010; Chapman and Jackson,
2008; Melander et al., 2008; Spycher et al., 2008; Wu et al.,
2008; Xu et al., 2008). Because BRCT domain phosphate-bind-
ing pockets can bind to both pSer and pThr peptides (Leung
et al., 2011), TopBP1 BRCT5 could potentially recognize only
the pSer, pThr, or even both phosphorylated residues. Here we
present the molecular basis for TopBP1 BRCT5 recognition ofl rights reserved
Figure 3. TopBP1 BRCT5 Diphosphopep-
tide Binding Interactions
(A) MDC1 peptide interactions with protomer A.
Hydrogen bonding and electrostatic interactions
are indicated by dotted lines and waters are
shown as red spheres. Different TopBP1 proto-
mers are designated as A and B.
(B) MDC1 peptide interactions with protomer B.
(C) Specificity of MDC1 peptide C-terminal resi-
dues by BRCT5 of protomer B in electrostatic
surface representation (left) and cartoon (right).
(D) Schematic diagram of MDC1 peptide in-
teractions with both TopBP1 BRCT5 protomers.
See also Figure S3.
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Structural Insights into MDC1-TopBP1 Interactiona MDC1 diphosphopeptide containing a consensus SDT repeat
sequence. Our structural and functional analyses not only pro-
vide insight into the questions raised above, but also reveal other
surprising aspects of BRCT phosphopeptide binding.
TopBP1 BRCT4/5 contains a number of structural features
that diverges from a conventional BRCT repeat. An unexpected
BRCT-BRCT packing interface results in a head-to-head
arrangement of the BRCT domains. This is a consequence of
an absent a2-helix and constraints imposed by the relatively
short inter-BRCT linker region. Rather than the a2-a1
0-a30 triple
helix bundle associated with typical BRCT repeat interfaces,
TopBP1 BRCT4/5 incorporates the same a1
0-a30 helices from
BRCT5 and a different surface composed of a3 and the b3-b4
loop from BRCT4. Unconventional BRCT-BRCT interfaces
have also been observed in the triple BRCT repeat, TopBP1
BRCT0/1/2, which coincidently also contains relatively shorter
inter-BRCT linkers. However, the interfaces between BRCT0/1Structure 21, 1450–1459, August 6, 2013 ªand BRCT1/2 are distinct from BRCT4/5
and their respective C-terminal domain
faces do not involve the a1
0 and a30 heli-
ces (Figure S1A; Rappas et al., 2011).
Another difference is the presence of a
phosphate-binding pocket in BRCT5
rather than the N-terminal BRCT4.
Although this is rare in tandem BRCT do-
mains, it is also found in the BRCT1/2 re-
peats in PAX-interacting protein 1 (PTIP)
for example (Sheng et al., 2011). It is not
clear, however, whether PTIP BRCT1/2
can bind phosphopeptides, and further
structural and functional work will be
needed to provide evidence for a com-
mon group of BRCT repeats that recog-
nize phosphopeptides via a C-terminal
BRCT pocket. Another possibility is that
BRCT5 phosphopeptide recognition
may in fact resemble phosphopeptide
binding of single BRCT domains, a func-
tion that still remains unclear.
A striking feature of the peptide-bound
structure is the lack of significant, tight
contacts between either the pSer or
pThr and the consensus phosphate-bind-
ing pocket of BRCT5. This is in contrastto all other structures of tandem BRCT domains bound to phos-
phopeptides where the phosphate is coordinated in a highly
conserved manner (Leung and Glover, 2011). Indeed, FP results
indicate that removal of both phosphate groups only results in
an 11-fold reduction in binding affinity, suggesting phosphory-
lation is less critical for TopBP1 BRCT4/5-phosphopeptide
recognition than for other tandem BRCT-target phosphopeptide
interactions. The lack of importance of the canonical phosphate-
binding pocket is further underlined by the fact that mutation of
the conserved Ser654 does not significantly impact phospho-
peptide binding affinity or TopBP1 foci formation (Figure 4).
This is in contrast with the analogous Ser1655 in the BRCA1
BRCT phosphate-binding pocket, which is critical for phospho-
peptide binding and for BRCA1 BRCT domain function (Lee
et al., 2010;Williams et al., 2004). Instead, phosphopeptide bind-
ing appears to largely rely on electrostatic interactions involving
not only the phosphate-binding pocket, but also the extended2013 Elsevier Ltd All rights reserved 1455
Figure 4. Mutational Analysis of the TopBP1 BRCT5 Binding Inter-
face
(A) Replication stress-induced focus formation of wild-type and TopBP1 mu-
tants. U2OS cells transfected with plasmids encoding SFB-tagged WT or
mutants of TopBP1 were exposed to 2 mM HU for 3 hr. Cells were fixed and
immunostained with anti-FLAG and anti-g-H2AX antibodies. Bar: 10 mm.
(B) FP binding studies of MDC1 FITC-labeled diphosphopeptide with GST-
fusion proteins of wild-type BRCT5 and various missense variants. Triplicate
data points are represented in graphs as mean ± SEM.
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0-b30 hairpin that contacts the conserved C-terminal acidic tail
of the MDC1 phosphopeptide motif.
Perhaps themost surprising aspect of phosphopeptide recog-
nition by TopBP1 BRCT5 is the apparent dimerization of BRCT5
induced by MDC1 binding. While the interface between
protomer B and the phosphopeptide is quite large and specific
mutations in its binding surface abrogate in vitro binding and
foci formation, the interface with protomer A is much smaller
and could be an artifact of crystal packing. We were unable to
isolate or trap the peptide-induced dimer in solution using gel-
filtration chromatography, chemical crosslinking, or EMSA.
This would suggest either that the binding of two BRCT4/5 pro-
tomers to a single MDC1 diphosphopeptide does not occur in
solution or that the interactions driving dimer formation with
the phosphopeptide may be too transient to form a tight com-
plex. On the other hand, we were able to demonstrate signifi-
cantly higher MDC1 di-phospho-peptide binding affinities for
dimeric GST-fusion proteins of BRCT4/5 than for monomeric
MBP-BRCT4/5 or BRCT4/5 alone (Figure 2A). An explanation
for this result could be that GST-induced dimerization indirectly1456 Structure 21, 1450–1459, August 6, 2013 ª2013 Elsevier Ltd Alstabilizes two BRCT4/5 domains in a state that favors the forma-
tion of the peptide-induced dimer observed in the crystal struc-
ture. If pairs of TopBP1 BRCT5 domains do bind phosphopep-
tide targets in the context of the intact full length protein, then
this would imply that other regions in TopBP1might be important
to stabilize TopBP1 oligomerization. Indeed, TopBP1 has been
shown to oligomerize through a tandem BRCT7/8-mediated
recognition of an Akt-dependent internal TopBP1 pSer
(pS1159) motif to stabilize the interaction between phospho-
E2F1 and the single BRCT6 domain of TopBP1 (Liu et al.,
2006). TopBP1 BRCT4/5 has also been shown to be important
for the colocalization of TopBP1 with 53BP1 at DNA double
strand breaks, where it may participate in the G1 DNA damage
checkpoint (Cescutti et al., 2010). While the details of this inter-
action have not been elucidated, it is intriguing that colocaliza-
tion and binding of the isolated BRCT4/5 with 53BP1 in cells
appears to be dependent on ATM as well as fusion of the
BRCT4/5 to a tetramerization domain. It is tempting to speculate
that BRCT4/5 may bind one or more of the highly acidic ATM
phosphorylation sites of 53BP1 (Jowsey et al., 2007) via a
dimeric mechanism similar to that observed in the TopBP1
BRCT4/5-MDC1 complex.
The highly conserved MDC1 SDT repeats are not only recog-
nized by TopBP1, but are also bound by the pThr-specific FHA
binding domains of aprataxin and the FHA-tandem BRCT
module of NBS1. Structural and biochemical studies of these in-
teractions reveal a primary recognition of pThr within the FHA
phosphate-binding pocket, with more limited electrostatic inter-
actions involving the pSer as well as neighboring acidic residues
in the pSDpT motif (Becherel et al., 2010; Lloyd et al., 2009; Wil-
liams et al., 2009). TopBP1 BRCT4/5, however, is distinct in its
recognition of the conserved +2 to +4 residues. This suggests
that the conservation of these residues in each of the SDT re-
peats in MDC1 is not solely for CK2 phosphorylation, but is
also critical for TopBP1 binding. Clearly, further investigation is
needed to understand how these diphosphopeptide motifs in
MDC1 are recognized by a host of proteins in DDR.
Like the TopBP1-BACH1 interaction, the interaction between
TopBP1 andMDC1 is also crucial for DNA replication checkpoint
control. This study provides the structural basis that underlies
another key TopBP1-mediated interaction that contributes to
ATR activation and checkpoint signaling. Moreover, MDC1 bind-
ing by TopBP1 BRCT5 uncovers certain aspects of BRCT
domain phosphopeptide recognition that further illustrate the di-
versity of BRCT domain function in the DNA damage response.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
TopBP1 BRCT5 (641-746) was cloned into pGEX-4T-1 and BRCT4/5 (549–
746) was cloned into pGEX-6P-1 (GE Healthcare) to create GST fusion pro-
teins. BRCT4/5 (549–746) was cloned into pKM596 (New England Biolabs)
to create an MBP fusion protein. BRCT5 mutants were engineered from
BRCT5 (641–746) using PCR-directed overlap extension (Heckman and
Pease, 2007) and cloned into pGEX-6P-1 vector. The GST fusion protein
was expressed in Escherichia coli BL21-Gold cells and purified using gluta-
thione affinity chromatography with glutathione sepharose 4B beads
(GE Healthcare) and eluted in elution buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 20 mM reduced glutathione, and 0.1% BME). GST-fusion pro-
tein of BRCT5 was cleaved with thrombin protease (GE Healthcare) overnight
at room temperature. BRCT5 was then separated from GST by cationl rights reserved
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buffer B: 50 mM HEPES pH 7, 1 M NaCl, and 0.1% BME). BRCT5 was further
purified on a Superdex 75 column in storage buffer (10 mM Tris-HCl pH 8,
150mMNaCl, and 1mMDTT). GST-TopBP1BRCT4/5 was cleavedwith PreS-
cission protease overnight at 4C. BRCT4/5 was purified by anion exchange
chromatography (buffer A: 50 mM HEPES pH 7 and 0.1% BME; buffer B:
50 mM HEPES pH 7, 1 M NaCl, and 0.1% BME). Residual GST was removed
by incubation with glutathione sepharose 4B beads (GE Healthcare) prior to a
final purification step on a Superdex 75 column in storage buffer (10 mM Tris-
HCl pH 7.5, 150 mM NaCl, and 1 mM DTT). The MBP-BRCT4/5 fusion protein
was expressed in E. coli BL21-DE3 cells and purified using amylose affinity
chromatography with amylose resin (New England Biolabs) and eluted in
elution buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 10 mM Maltose, 1 mM
EDTA, and 0.1% BME). MBP fusion protein was purified by anion exchange
chromatography (buffer A: 50 mM HEPES pH 7, and 0.1% BME; buffer B:
50mMHEPES pH 7, 1MNaCl, and 0.1%BME) and further purified on a Super-
dex 75 column in storage buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, and
1 mM DTT). The size and oligomeric state of each of the proteins was
confirmed by size exclusion chromatography on a Superdex 75 column cali-
brated with protein size standards.
Crystallization
TopBP1 BRCT5 was concentrated to 9mg/ml for crystallization. Crystals were
grown at 4Cusing hanging drop vapor diffusion by adding 2 ml protein with 1 ml
reservoir consisting of 10% PEG 1000 and 0.1 M Na/K phosphate pH 6.2.
Crystals were flash-cooled in cryoprotectant containing reservoir solution
and 26% glycerol. TopBP1 BRCT4/5 was concentrated to 6.5 mg/ml for crys-
tallization. Crystals were grown at room temperature in drops containing 1 ml
protein and 1 ml reservoir (20% PEG 3350 and 0.2 M NaSCN). Cryoprotectant
used to flash-cool crystals contained reservoir solution supplemented with
15% glycerol. For cocrystallization, TopBP1 BRCT4/5 concentrated to
12 mg/ml was incubated with a 1:6 molar ratio of protein:peptide (Ac-
GFIDpSDpTDVEEE-NH2) for 1 hr on ice. Cocrystals were grown at room tem-
perature by adding 1 ml of protein:peptide mixture with 1 ml of reservoir solution
containing 0.1 M ammonium acetate, 0.1 M bis-Tris pH 5.5and 17% PEG
10,000. Cocrystals were flash-cooled in reservoir solution supplemented
with 20% glycerol.
Data Collection and Structure Determination
Data for BRCT5 and BRCT4/5 crystals were collected at the 8.3.1 beamline
(Advanced Light Source, Berkeley). Intensity data from a BRCT5 crystal
were processed using HKL2000 (Otwinowski and Minor, 1997) to the space
group P6222 with unit cell dimensions a = 91.00 A˚, b = 91.00 A˚, c =
114.31 A˚, a = 90, b = 90, and g = 120. A starting model consisting of an
ensemble of N-terminal BRCT domains (Protein Data Bank [PDB] IDs: 1JNX,
1R1Z, and 2ADO) was used in molecular replacement with PHASER (McCoy,
2007). The solution was then partially built in COOT (Emsley andCowtan, 2004)
and refined to 3.3 A˚ resolutionwith TLS and restrained refinement in REFMAC5
(Murshudov et al., 1997) to a Rwork andRfree of 0.3887 and 0.4256, respectively.
Data from a BRCT4/5 crystal were scaled and reduced to the space group
P2221 with unit cell dimensions a = 35.90 A˚, b = 48.80 A˚, c = 126.09 A˚, a =
90, b = 90, and g = 90. The partially refined BRCT5 structure was used in
molecular replacement to find one BRCT4/5 molecule in the asymmetric
unit. Further refinement with rigid body and restrained refinement in REFMAC5
prior to automated model building using ARP/wARP (Cohen et al., 2008) suc-
cessfully built 191 total residues with side chains. Further model building in
COOT and refinement using PHENIX (Adams et al., 2010) at 1.9 A˚ resolution
yielded a final Rwork and Rfree of 0.175 and 0.224, respectively. The final model
lacks the N-terminal 549 residue and C-terminal 745–746 residues due to dis-
order in the crystal. The Ramachandran plot contains 100% of all residues in
favored regions and 0% in outlier regions.
Data for crystals of the BRCT4/5-peptide complex were collected at the
CMCF 08ID-1 beamline (Canadian Light Source, Saskatoon). Intensity data
were scaled and reduced using the XDS package (Kabsch, 2010) to the space
group P1 with unit cell dimensions a = 58.81 A˚, b = 59.10 A˚, c = 78.31 A˚, a =
102.05, b = 98.04, and g = 114.34. The apo BRCT4/5 structure was used
in PHASER to successfully find 4 copies in the asymmetric unit. Model building
was carried out in COOT and refined using TLS refinement (1 group/chain) andStructure 21, 14502-fold NCS restraints in PHENIX. The BRCT4/5 molecules are arranged as two
dimers (designated AB and CD) related by 2-fold noncrystallographic symme-
try (Figure S2B). BRCT4/5 molecules A and C lack the N-terminal 549–550 res-
idues, C-terminal 742–746 residues, and loop residues 584–588. Molecules B
andD lack the N-terminal 549–550 residues, C-terminal 743–746 residues, and
loop residues 584–589. The BRCT4/5 molecules were fully refined before
building of the two peptides. Peptide A lacks the N-terminal 6 residue and
C-terminal +5 residue and peptide B lacks the N-terminal 6 to 4 residues
and C-terminal +5 residue (Figure S3B). Because there are slight deviations
in the two peptide chain conformations (Figure S3C), 2-fold NCS restraints
were not imposed for the peptide chains during refinement, which also yielded
the lowest Rfree statistics. The wxu_scale was set to 0.1 to reduce the X-ray/
ADPweight. The final model was refined in Phenix at 2.6 A˚ resolution to a Rwork
and Rfree of 0.190 and 0.234, respectively. The Ramachandran plot contained
96.8% of all residues in favored regions, 3.0% in allowed regions, and 0.3% in
outlier regions.
Data collection and refinement statistics for the apo and peptide-bound
structures are listed in Table 1. Models were validated with MolProbity
(Chen et al., 2010). Secondary structure prediction of the models was per-
formed with DSSP (Kabsch and Sander, 1983) and converted using
DSSP2PDB (http://structure.usc.edu/dssp2pdb/). Hydrogen bonding was
verified using HBPLUS (McDonald and Thornton, 1994). Structure figures
were prepared with PyMOL (Version 1.4, Schro¨dinger).
Fluorescence Polarization
FP measurements were carried out using an Envision multi-label plate reader
(Perkin Elmer) on a 384-well OptiPlate (Perkin Elmer). All peptideswere synthe-
sized and purified by Biomatik. FP assays were performed by mixing 10 nM
FITC-labeled MDC1 phosphopeptide (FITC-GFIDpSDpTDVEEE-NH2; FITC-
GFIDpSDpTDDEEE-NH2; FITC-GFIDSDpTDVEEE-NH2; FITC-GFIDpSDTD
VEEE-NH2; FITC-GFIDSDTDVEEE-NH2) with freshly concentrated TopBP1 in
FP assay buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT, and
0.05% Tween-20). The wells were incubated for 15 min at room temperature
prior to taking FP measurements at an excitation wavelength of 485 nm and
emission wavelength of 538 nm. Curve fitting and Kd calculations were ob-
tained using PRISM software (GraphPad). Kd values presented in Table 2
are the averages from at least three independent titrations.
Immunofluorescence Staining
Cells grown on coverslips were treated with HU (2 mM) for 3 hr. Cells were
fixed in 3% paraformaldehyde for 10 min, and then permeabilized in 0.5%
Triton X-100 containing solution for 5 min. Cells were incubated with primary
antibodies diluted in 5% goat serum at room temperature for 30 min. Cells
were washed twice with PBS and then incubated with either FITC-conjugated
or rhodamine-conjugated secondary antibodies at room temperature for
30 min. Nuclei were counterstained with DAPI. The coverslips were mounted
onto glass slides with antifade solution and depicted using a Nikon Eclipse
E800 fluorescence microscope with a 60 3 NA 1.3 oil objective lens. Images
were photographed and analyzedwith a Spot 2Megasample camera and Pho-
toshop software (Adobe).
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